Quality controls of cryopreserved hematopoietic stem cells by Daniele, Nicola & Zinno, Francesco
Review/Praca poglądowa
Quality controls of cryopreserved hematopoietic
stem cells
Nicola Daniele *, Francesco Zinno
Immunohematology Section, Tor Vergata University and CryoLab – Stem Cells Manipulation and Cryopreservation
Laboratory, Rome, Italy
a c t a h a e m a t o l o g i c a p o l o n i c a 4 6 ( 2 0 1 5 ) 3 4 7 – 3 5 2










a b s t r a c t
HPC processing has been performed routinely for many years for the preparation and
cryopreservation of HPC used for autologous and allogeneic transplantation. JACIE Stan-
dards (section D) regulate HPC processing and request that processing is performed
within the framework of a quality management system (QMS). Implementing QMS in
HPC-processing laboratories is feasible, and many processing laboratories are already
accredited according to various standards.
Before hematopoietic stem cell transplantation, it is recommended that accurate qua-
lity controls be performed to assess the median number of viable CD45+/7-aminoactino-
mycin-D (7-AAD) and CD45+/CD34+/7-AAD cells, the presence of microbiologic contami-
nation, and the proliferative potential of hematopoietic progenitor cells. The guidelines
for the determination of the QCs have been established by FACT/JACIE standards.
To be optimal, process and quality controls have to be performed in a real-time manner
in order to ensure safe product release and an immediate recognition of deviations. Fur-
thermore, the immediate initiation of corrective measures is crucial for risk prevention.
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Hematopoietic stem cell transplantation is a field of enormous
therapeutic advances and worldwide expansion of applica-
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following experiments in mice that showed protection
against the lethal effects of irradiation, by the intravenous
infusion of donor bone marrow containing hematopoietic
cells capable of colonizing the recipient's bone marrow.
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kill, with the subsequent infusion of hematopoietic progenitor
cells in order to circumvent the myelo and immunoablative
effects of the preparative regimen [1–3]. More recently less
intensive conditioning regimens have been utilized, often in
older individuals, in an effort to reduce transplant related
morbidity and mortality, while still capturing the potent graft
versus tumor effect of an allogeneic HSCT. HSCT can be
broadly classified according to donor source: autologous and
allogeneic. Autologous HSCT involves the administration of
myeloablative doses of chemoradiotherapy, followed by the
infusion of previously collected autologous (self-donor) cells.
Allogeneic HSCT refers to the transplantation of hematopoie-
tic cells from a donor other than the patient [4–6].
The “quality” in a transplant program
HSCT as a discipline continues to rapidly evolve through
translation of discoveries in the basic and clinical aspects of
immunology, oncology, and infectious diseases into the
transplant clinic. The continuing evolution of clinical care
and the diverse group of patients and diseases treated with
HSCT have contributed to disagreement as to how to
establish measures of quality in transplant programs [7].
Quality of health care remains a topic of intense interest at
all levels of the health-care delivery system. Measurement
of quality in no less important in HSCT than in other areas
of medicine and may even be more important, for a host of
reasons. These include the life-threatening nature of the
diseases, the treatment, the opportunity for cure, the
intensive resource utilization, the manipulation of cells and
the involvement of healthy donors in HSCT. It is quite likely
that results of all transplant centers do not yield equivalent
outcomes. Despite the acceptance of HSCT as the standard
of care, meaningful measures of program quality are still in
development [8].
The JACIE standards
Early after the initiation of FACT accreditation, the Joint
Accreditation Committee European Group for Blood and
Marrow Transplantation-Euro-ISHAGE (JACIE) was estab-
lished. JACIE standards aim to promote and maintain the
quality of medical and laboratory practice in HPC transplan-
tation and to ensure harmonization between JACIE stan-
dards and other national/international standards. JACIE
accreditation is voluntary, but provides a means whereby
transplant facilities can demonstrate that they are working
with a quality system covering all aspects of the transplan-
tation process [9, 10]. The JACIE standards cover all aspects
of clinical transplant programs, collection facilities and
processing. The JACIE standards also apply to the use of
therapeutic cells derived from blood or marrow including
donor lymphocytes and mesenchymal stem cells. The JACIE
accreditation system is now firmly established in Europe,
and the experience of centers that have been inspected
are that implementation of the JACIE standards has led
to significant improvements in different aspects of theirtransplant programs. JACIE has further assisted with
a number of training courses for preparing centers for
accreditation and has issued a practical guide for quality
management. JACIE has developed a close working relation-
ship with other organizations involved in cellular therapy,
which form the basis for a new global approach to harmoni-
zation of standards and accreditation systems worldwide
[11, 12].
A milestone: the “Directive 2004/23/EC” of the
European Parliament
In March 2004, Directive 2004/23/EC set standards for the
donation, procurement, testing, processing, preservation,
storage, and distribution of human tissues and cells. For the
first time in the area of tissues and cells, a binding suprana-
tional, transparent, and sound regulatory framework had
arisen, providing all citizens with the same minimum
guarantees of quality and safety [13]. It is well specified that
each tissue center must put in place a quality control
system, which must include at least the following informa-
tion: guidelines; operating procedures; training and refer-
ence manuals; donor records (to be kept for at least 30
years); information on the final destination of tissues or
cells. Moreover, tissue establishments must include in their
operating procedures all the processes that affect quality
and safety. They must ensure that the equipment used, the
working environment and process monitoring conditions
comply with the requirements regarding the processing,
storage and distribution of tissues and cells.
The obligations for Member States dictated in Directive
2004/23/EC are:
(1) designation of a Competent Authority;
(2) supervision of human tissue and cell procurement;
(3) accreditation, designation, authorization, or licensing of
Tissue Establishments and tissue and cell preparation
process;
(4) implementation of a system of inspections and control
measures;
(5) implementation of a system of traceability;
(6) guarantee on quality and safety of imported/exported
human tissues and cells;
(7) Register of Tissue Establishments and reporting obliga-
tions;
(8) notification of serious adverse events and reactions
[13, 14].
Aspects of donors selection
Donor and patient HLA match status should be used to
assess the risk of transplantation and to plan treatment
based on those risks. The benefits of high-resolution HLA
class I and II typing have been well demonstrated, particu-
larly in post-transplant survival [15].
Moreover, the possibility of infection transmission by
infusion of cryopreserved peripheral blood stem cells con-
centrates (PBPC) or bone marrow (BM) is well known. For this
reason, the European Blood and Marrow Transplantation
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and Graft Engineering (ISHAGE) standards include a panel of
serological tests to be performed in donors with the aim of
lowering the likelihood of infection transmission.
In addition, choice of donor source is dependent on the
indication for HSCT, its urgency, the age of the patient, and
the expertise and resources of the center [16].
Although the donation process is generally considered
safe, side effects are a known risk, and care must be taken
to minimize the potential of harm to donors.
In a prospective study, Billen et al. found that predona-
tion health-related quality of life markers were the most
important factors associated with recovery and the develop-
ment of side effects, more so than any demographic variable
[17].
The importance of “quality controls”
In hematopoietic stem cell transplantation, the final quality
control of cryopreserved progenitor cells is a successful and
persistent three lineage engraftment after transplantation.
The stem cell providing institution is obliged to have
a program for controlling and monitoring the manufacturing
of cellular therapy products before the patients’ condition-
ing therapy is started. The FACT–JACIE standards prescribe
that the director of the institute shall define tests and
procedures for measuring and assaying cellular therapy
products to ensure their safety, viability and integrity and
shall also ensure that products meet predetermined release
specifications [18]. This requires specifications of assays and
the definition of thresholds to allow release. The most
common cell viability test is still trypan blue dye exclusion,
although its predictive value is low and it does not seem to
be a substitute for assays evaluating in vitro proliferative
capacity. Stem cell culture assays are time consuming and
results are investigator-dependent. Furthermore, flow cyto-
metry-based evaluation of viability or apoptosis markers of
progenitor cells after freezing–thawing are not standardized
[19]. Reduced numbers of viable CD34+ cells have been
reported to be associated with a risk of delayed platelet
engraftment or graft failure. Further it has to be mentioned
that interlaboratory discrepancies in the results of the
assays exists, due to the fact that standardization is difficult
and that the performance is variable. These problems can
only be overcome by participating in external proficiency
testing and by individual validation studies to establish
specifications for release in each center [20].
The UK NEQAS Program
UK NEQAS for Leukocyte Immunophenotyping is an interna-
tional External Quality Assessment (EQA)/Proficiency Testing
(PT) provider hosted by, and is legally accountable to,
Sheffield Teaching Hospitals NHS Foundation Trust. UK
NEQAS LI was established as a regional program in 1986. At
that time a total of 20 UK laboratories participated in the
single program available at that time. Currently, there are
over 1700 active registrations worldwide within the 20programs now operated by the center [21]. In haematopoie-
tic stem cell transplantations the use of CD34+ stem cell
enumeration is an essential part of the treatment process,
allowing for monitoring of donor mobilization pre harvest
and to ensure sufficient cells are collected to ensure engraft-
ment will occur. CD34+ Stem Cell Program is currently the
largest world-wide for CD34+ haematopoietic progenitor cell
enumeration [22]. The program uses stabilized peripheral
blood obtained from consenting patients following stem cell
mobilization and is suitable for use with whole blood lysis
techniques and sequential gating strategies. Laboratories are
requested to report both percentage and absolute values (in
cells per microlitre), although performance is only moni-
tored using the absolute values. Two samples are issued per
trial and this program issues trials a minimum of 4 times
per annum and a maximum of 6 [23].
The enumeration of CD34+ cells
The CD34 antigen is present on immature hematopoietic
precursor cells and hematopoietic colony-forming cells in
bone marrow and blood, including unipotent and pluripo-
tent progenitor cells. An accurate measure of CD34+ cell
count is necessary for dose requirement protocols on stem
cell transplantation. CD34+ cell count is the most widely
used biologic parameter for monitoring progenitor cell
mobilization and apheresis, as well as assay the quality of
most, if not all, types of hematopoietic cell grafts for
autologous and allogeneic transplantation. International
guidelines for flow cytometric enumeration of CD34+ hema-
topoietic stem cells (HSC) recommend the use of a single-
platform assay [24]. Currently, the two most frequently used
single platform kits are the Stem-KitTM enumeration kit
(manufactured by Beckman-Coulter, Villepintes, France)
[25] and ProCountTM kit (manufactured by BD Biosciences,
Meylan, France) [26]. Stem-Kit allows CD34+ cell enumera-
tion in all types of HSC; it includes software designed for
Beckman Coulter cytometers, which uses the ISHAGE gating
strategy and allows automated or semi-automated produc-
tion of results. The ISHAGE protocol is the most reliable
method currently available to quantitate accurately this
important subset of cells. ProCount is validated for fresh
(non-cryopreserved) apheresis and peripheral blood sam-
ples only; it does not include a viability reagent. This kit
comes with specific software designed for BD Biosciences
cytometers that uses a Boolean strategy for data analyses,
and allows automated production of results. The two kits
produce well-correlated results. The major limitations of
ProCount are its restrictive use for fresh apheresis and
blood samples, and a short stability (few weeks) of the anti-
CD45–PerCP antibody. BD Biosciences recently commercia-
lized the SCETM (stem cell enumeration) kit that addresses
these limitations by integrating an antibody combination
(CD45–FITC, CD34–PE), a viability dye 7-amino-actinomycin-
D (7-AAD) and an NH4–Cl lysis reagent. The kit also
includes TrucountTM tubes, containing known numbers of
microbeads; this avoids bead pipetting, which decreases
test precision. Because of these potential improvements,
the SCE kit could be used to enumerate CD34+ cells in all
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cord blood (CB)], fresh and thawed [27].
The apoptosis in HSCT
Before the hematopoietic stem cells reinfusion, the QCs
consist of a total nucleated cell count, the viability assess-
ment of both CD45+/7-AAD cell population and CD45+/CD34
+/7-AAD subpopulation through flow cytometry, and the
evaluation of proliferative capacity. The clonogenic assays
consist of a 14-day incubation at 37 8C and CFU dose infused
to the patient is one of the best markers of graft outcome.
Therefore, it is necessary to perform the QCs at least 14
days before the transplantation to obtain a complete evalua-
tion of the cryopreserved HPC unit. It should be important
to have a rapid and efficient test in association with flow
cytometry as a satisfactory QC of the HPC units before the
reinfusion to the patient to have preliminary indications that
allow clinicians to proceed with the transplantation before
the clonogenic tests results [28]. For this purpose, in a paper
Scerpa and colleagues described the use of the new instru-
ment NucleoCounter NC-3000. The NucleoCounter NC-3000
enables automated cell counting and analyses of a wide
number of samples to be performed at the same time; it is
easy to use and also guarantees an excellent precision
reducing the data variability due to the operator's work. Other
tests used in the clinical routine, such as the determination
of cell viability with trypan blue, are characterized by a huge
variability of the results. In particular, two different Nucleo-
Counter NC-3000 protocols, both related to the evaluation of
cell functionality, have been used in the study of Scerpa et al.
[28]. The quantification and detection of apoptotic cells was
determined by the protocol “mitochondrial potential assay,”
which correlates the loss of the mitochondrial membrane
potential and the early stage of apoptosis and chemical
hypoxia-induced necrosis. Instead, the protocol “vitality
assay: analysis of the level of cellular thiols” was applied to
evaluate the detection of changes in the cellular level of
reduced thiols directly related to apoptosis [29, 30].
Microbial contamination of hematopoietic stem
cells products
Microbial safety of the hematopoietic progenitor cell (HPC)
product is an important issue for successful HCT and is
regarded as a quality marker of good medical practice. HSCT
involve many different steps including harvesting of bone
marrow or peripheral blood progenitor cells, processing for
cryopreservation, freezing, thawing and finally infusion [31].
Despite using sterile precautions all of these steps are prone
to contamination. The incidence of microbial contamination
of stem cell products have been reported as 0.2–26.3% [32,
33]. Such a wide range of reported contamination rates may
be related to different stem cell sources of studies, time
dependent improvement of collection and processing sys-
tems, variations in harvesting and processing protocols of
centers, and experience of apheresis teams. In addition,
frequency of using central venous catheters (CVC) for HPCcollection probably influence the rate of microbial contam-
ination of products, as infections associated with CVCs are
important factors for HPC contamination [34, 35].
The sterility testing process of hematopoietic stem
cells
To decrease the risk of serious transplantation-transmitted
infections, the current good tissue practices recommends
avoiding the processing of stem cells from donors with
positive cultures for pathogenic or enteric bacteria unless
a final sterilization step is expected during product proces-
sing. In some hospitals, it is accepted that contaminated
HSC products be transplanted if there are no other options
for patient treatment. In these cases, an antibiotic therapy
is applied based on the antimicrobial susceptibility of the
contaminant microorganism [36, 37]. As required by cellular
therapy accrediting organizations such as AABB and the
Foundation for Accreditation of Cellular Therapy (FACT), cell
therapy products must be tested for microbial contamina-
tion. In addition, as required by the Food and Drug Admin-
istration (FDA) Code of Federal Regulations, a validated
testing method such as biologic sterility test immersion or
membrane filtration must be used by the testing laboratory.
Although automated culture systems are not FDA approved
for sterility testing of human cellular therapy products or
cellular-based products, both BacT/ALERT 3D (bioMérieux,
Durham, NC) and Bactec 9240 (Becton Dickinson Franklin
Lakes, NJ) systems are widely used [38, 39]. According to
Khuu and coworkers, these two automated systems are
more sensitive and specific and faster in detecting microbial
contamination in cell therapy products than the Code of
Federal Regulations methods [40]. It should be highlighted
that PBPCPs should be processed in clean areas with air
locks for personnel and equipment to minimize the risk of
bacterial contamination during processing. This includes the
particulate and microbiologic monitoring during various
grades in operation as well as the control of surfaces and
personnel after critical operations [41].
Conclusion
Hematopoietic stem cell transplantation is routinely used
for the treatment of numerous oncohematologic malignan-
cies. The stem cells collected by apheresis undergo minimal
manipulation procedures such as volume reduction and
cryopreservation [42, 43]. In particular, the cryopreservation
and thawing procedures represent the crucial point of the
whole process and may also affect the viability of hemato-
poietic stem cells contained in the HPC units. For this
reason it is necessary to perform accurate QCs before the
hematopoietic stem cells reinfusion [44, 45].
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